Target intelligence / Profile preview

Enterovirus capsid proteins VP1–VP4 (VP1–VP4)

Target
VP1–VP4
Molecular classification
Viral structural protein, Capsid protein
01

Overview

Enterovirus capsid proteins VP1, VP2, VP3, and VP4 are the structural components that form the icosahedral shell of viruses within the Enterovirus genus, including poliovirus, coxsackievirus, and rhinovirus. VP1, VP2, and VP3 are located on the external surface of the virion and are responsible for host cell receptor recognition and antigenic properties, while VP4 is situated internally and plays a critical role in genome release. These proteins are essential for the viral life cycle, mediating attachment to host cells and the subsequent uncoating of the viral RNA genome. In clinical medicine, these proteins are the primary targets for 'capsid binders,' small molecules that lodge in a hydrophobic pocket of VP1 to stabilize the capsid and inhibit infection. Despite their potential, the high rate of mutation in enteroviruses often leads to the development of resistance, posing a significant challenge for therapeutic development.

Other names
Enterovirus structural proteinsPicornavirus capsid proteinsVP1VP2VP3VP4Capsid protein VP1Capsid protein VP2Capsid protein VP3Capsid protein VP4
02

Mechanism of action

Capsid binders occupy a hydrophobic pocket (the 'canyon' or 'pocket') within the VP1 protein, which increases the rigidity of the viral capsid. This stabilization prevents the conformational changes necessary for the virus to attach to host cell receptors or prevents the uncoating process required to release the viral RNA into the host cytoplasm.

03

Biological functions

Viral entryViral attachmentViral uncoatingGenome packagingHost cell receptor bindingAntigenic determinant
04

Disease associations

InfectionPoliomyelitisHand, foot, and mouth diseaseMyocarditisAseptic meningitisCommon coldSevere respiratory illness
05

Safety considerations

Rapid emergence of drug-resistant viral variantsNarrow spectrum of activity across different enterovirus serotypesDrug-drug interactions (e.g., Pleconaril induces CYP3A enzymes)Limited clinical efficacy in some trials
06

Interacting drugs

Pleconaril

6 more in the full profile.

07

Biomarkers

Viral load (RNA) in stool or respiratory swabsVP1-specific antibodiesSerum neutralizing antibody titers

Beyond the preview

Go deeper on Enterovirus capsid proteins VP1–VP4 (VP1–VP4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterovirus capsid proteins VP1–VP4 (VP1–VP4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call